Drug intelligence / Profile preview

RS-003

Development stage: Preclinical
Lead developer: Redesign Science
Modality: Small Molecules

Overview

RS-003 is a preclinical small molecule drug candidate being developed by Redesign Science for the treatment of hematologic cancers. It is designed as a Targeted Protein Interaction Modulator (TPIM™) using the company's proprietary NUVO™ technology platform, which utilizes physics-based molecular dynamics to identify novel binding sites. RS-003 specifically targets an apoptotic factor to modulate protein-protein interactions involved in programmed cell death, with the goal of inducing apoptosis in malignant blood cells. As of early 2024, the program is in the hit-to-lead stage of preclinical development.

Targets

AIFM1 (Apoptosis-inducing factor mitochondria-associated 1)

Beyond the preview

Go deeper on RS-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS-003.

Explore the full profile